Segment Information - Reportable Segment Information (Detail) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Net sales:
Net sales	$ 2,820	$ 3,063	$ 8,776	$ 9,596
Segment Adjusted Operating EBITDA:
Adjusted Operating EBITDA	506	612	1,519	2,014
Other Depreciation and Amortization	292	293	855	897
Interest expense	(110)	(83)	(337)	(232)
Other income, net	19	33	34	43
Restructuring and other charges, net	(2)	4	(61)	(5)
Impairment of goodwill	0	2,250	0	2,250
Acquisition, divestiture, and integration related costs	42	57	118	167
Strategic initiative costs	(6)	(1)	(28)	(1)
Regulatory costs	(13)	0	(32)	0
Other gains (losses)	1	0	(1)	5
Income before taxes	59	(2,035)	123	(1,620)
Business divestiture costs	(29)	(31)	(70)	(91)
Integration-related costs	(12)	(25)	(42)	(73)
Transaction related costs	(1)	(1)	(6)	(3)
Impairment of long-lived assets	0	0	0	(120)
Nourish
Segment Adjusted Operating EBITDA:
Restructuring and other charges, net	(1)	0	(33)	(3)
Health & Biosciences
Segment Adjusted Operating EBITDA:
Restructuring and other charges, net	(1)	(1)	(12)	(2)
Impairment of goodwill		2,250		2,250
Scent
Segment Adjusted Operating EBITDA:
Restructuring and other charges, net	0	5	(14)	0
Pharma Solutions
Segment Adjusted Operating EBITDA:
Restructuring and other charges, net	0	0	(2)	0
Operating Segments | Nourish
Net sales:
Net sales	1,449	1,703	4,666	5,252
Segment Adjusted Operating EBITDA:
Segment Adjusted Operating EBITDA	178	287	567	981
Operating Segments | Health & Biosciences
Net sales:
Net sales	518	512	1,553	1,838
Segment Adjusted Operating EBITDA:
Segment Adjusted Operating EBITDA	150	137	426	513
Operating Segments | Scent
Net sales:
Net sales	615	591	1,815	1,756
Segment Adjusted Operating EBITDA:
Segment Adjusted Operating EBITDA	131	119	353	328
Operating Segments | Pharma Solutions
Net sales:
Net sales	238	257	742	750
Segment Adjusted Operating EBITDA:
Segment Adjusted Operating EBITDA	$ 47	$ 69	$ 173	$ 192